A Phase 1/2 interventional study of VXA-G1.1-NN in Norovirus Infections, sponsored by Vaxart. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-22.
Sponsored by Vaxart · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Caliciviridae Infections with a site in United States — none open to participants now, none under way, none of them phase 3. Caliciviridae Infections · United States.
Among the 11 studies in Caliciviridae Infections with a site in United States, this one is the 8th largest by enrollment, is one of 3 that started in 2021, is one of 3 in phase 1/2, and was the 6th registered.
20 studies on the registry are indexed under Caliciviridae Infections; 2 are open to participants now.
Browse Caliciviridae Infections studies →None of the 11 studies in Caliciviridae Infections with a site in United States is open now. The open studies under Caliciviridae Infections, anywhere →
Of the 2 Caliciviridae Infections studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 4
First in 2011; this study’s year is marked. 3 started in 2021.
This study's enrollment of 30 is below the median of 71 across 18 interventional studies indexed under Caliciviridae Infections.
Median enrollment 60 across the 11 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 4 most frequent:
Vaxart is the lead sponsor of 23 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 6 (43%) have results posted.
Vaxart has 8 studies filed under Caliciviridae Infections — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Caliciviridae Infections with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the immunogenicity of VXA-G1.1-NN with repeat-dose administration at Day 1 and varying boost schedules (Week 4, 8 or 12 post initial dose) in healthy adults aged 18-55, inclusive, and to assess the safety and tolerability of VXA- G1.1-NN with repeat-dose administration at varying boost schedules (Week 4, 8 or 12) in healthy adults aged 18-55, inclusive
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age
18 to 55 years old inclusive at the time of signing the Form (ICF).
Type of Participants
Available for all planned visits and phone calls, and willing to complete all protocol- defined procedures and assessments (including ability and willingness to swallow multiple small enteric-coated tablets per study dose).
Gender and Reproductive Considerations
Male or female participants use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
a. Female participants must provide a negative pregnancy test at each required visit and fulfill one of the following criteria:
Informed Consent
Exclusion Criteria:
Medical Conditions
History of irritable bowel disease or other inflammatory digestive or gastrointestinal condition that could affect the distribution/safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine.
Such conditions may include but are not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(4-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU ± 0.5 log at Day 1 and Week 4
Biological: VXA-G1.1-NN
(8-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU± 0.5 log at Day 1 and Week 8
Biological: VXA-G1.1-NN
(12-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU± 0.5 log at Day 1 and Week 12
Biological: VXA-G1.1-NN
Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with double-stranded RNA Adjuvant
Viral-capsid Protein 1 (VP1)-Specific Antibody Secreting Cells (ASC) by Enzyme-linked Immunospot (ELISpot) Assay
Comparison of VPI specific immunoglobin A (IgA) ASC levels between the 3 study cohorts by enzyme-linked immunospot (ELISpot) assay
Time frame: Day 1 (Initial Vaccination) through Day 8 post boost (Second Vaccination)
Norovirus G1.1 Histo-blood Group Antigen (HBGA) Blocking Antibodies (BT50) Assay
Comparison of subjects with a ≥2-, 3- or 4-fold increase over baseline titer of GI.1 histo-blood group antigen (HBGA) blocking antibodies (BT50) levels between the 3 study cohorts.
Time frame: Day 1 (Initial Vaccination) through Day 29 post boost (Second Vaccination)
VP1 Serum Immunoglobin G (IgG) by Mesoscale Discovery (MSD) Assay
Comparison of VPI specific immunoglobin A (IgA) ASC levels by Mesoscale Discovery (MSD) assay between the 3 study cohorts
Time frame: Day 1 (Initial Vaccination) through Day 29 post boost (Second Vaccination)
Norovirus G1.1 Histo-blood Group Antigen (HBGA) Blocking Antibodies (BT50) Assay
Comparison of GI.1 histo-blood group antigen (HBGA) blocking antibodies (BT50) levels between the 3 study cohorts
Time frame: Day 1 (Initial Vaccination) through Day 29 post boost (Second Vaccination)
Solicited Symptoms of Reactogenicity
Comparison of frequency, duration, and severity of solicited symptom events in participants
Time frame: Day 1 (Vaccination) to Day 8 post each vaccination
Unsolicited Adverse Events (AEs)
Comparison of the frequency, duration, and severity of unsolicited AEs and serious AEs (SAEs) including AEs of Special Interest (AESIs) and new onsets of chronic illness (NOCIs) in participants
Time frame: Day 1 (Vaccine) through 28 days following boost (Second Vaccination)
Long-term Safety
Frequency, duration, and severity of all SAEs, AESIs and NOCIs through 6 months after last vaccination.
Time frame: Day 1 (Vaccine) through 6 months following boost (Second Vaccination)
| Milestone | Cohort 1 (4-week Boost Vaccination) | Cohort 2 (8-week Boost Vaccination) | Cohort 3 (12-week Boost Vaccination) |
|---|---|---|---|
| Started | 10 | 10 | 10 |
| Completed | 9 | 10 | 10 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
Comparison of VPI specific immunoglobin A (IgA) ASC levels between the 3 study cohorts by enzyme-linked immunospot (ELISpot) assay
| Spot Forming Units per 10^6 PBMC | Cohort 1 (4-week Boost Vaccination) | Cohort 2 (8-week Boost Vaccination) | Cohort 3 (12-week Boost Vaccination) |
|---|---|---|---|
| First Dose | 1.3 (-0.4 to 3.0) | 0.5 (-0.4 to 1.3) | 0.3 (-0.2 to 0.8) |
| 7-Days post First Dose | 127.6 (23.8 to 231.4) | 214.3 (15.8 to 412.9) | 327.5 (-106.4 to 761.4) |
| Second Dose | 2 (0.1 to 4.0) | 2.1 (-1.1 to 5.2) | 2.3 (-0.3 to 4.8) |
| 7-Days post Second Dose | 25.5 (-6.2 to 57.2) | 68.8 (-29.4 to 167.0) | 132.1 (-16.1 to 280.4) |
Comparison of subjects with a ≥2-, 3- or 4-fold increase over baseline titer of GI.1 histo-blood group antigen (HBGA) blocking antibodies (BT50) levels between the 3 study cohorts.
| 10^6 AU/mL | Cohort 1 (4-week Boost Vaccination) | Cohort 2 (8-week Boost Vaccination) | Cohort 3 (12-week Boost Vaccination) |
|---|---|---|---|
| Day of First Dose: GMC (geometric mean concentration) | 29.9 (17.0 to 52.6) | 27.9 (12.8 to 60.9) | 21.1 (12.0 to 37.1) |
| 28-Days post First Dose: GMC (geometric mean concentration) | 52.7 (28.8 to 96.2) | 69.5 (23.2 to 208.4) | 54.9 (18.7 to 161.2) |
| 28-Days post Second Dose: GMC (geometric mean concentration) | 74.5 (36.9 to 150.4) | 54.0 (19.0 to 153.8) | 64.9 (24.4 to 172.8) |
Comparison of VPI specific immunoglobin A (IgA) ASC levels by Mesoscale Discovery (MSD) assay between the 3 study cohorts
| 10^6 AU/mL | Cohort 1 (4-week Boost Vaccination) | Cohort 2 (8-week Boost Vaccination) | Cohort 3 (12-week Boost Vaccination) |
|---|---|---|---|
| First Dose: GMC (geometric mean concentration) | 0.5 (0.1 to 2.1) | 0.3 (0.1 to 1.2) | 0.2 (0.0 to 1.1) |
| 28-Days post the First Dose: GMC (geometric mean concentration) | 2.1 (0.9 to 4.9) | 2.6 (0.8 to 8.7) | 2.1 (0.4 to 11.2) |
| 28-Days post the Second Dose: GMC (geometric mean concentration) | 1.5 (0.6 to 3.9) | 1.2 (0.4 to 3.6) | 1.7 (0.5 to 6.1) |
Comparison of GI.1 histo-blood group antigen (HBGA) blocking antibodies (BT50) levels between the 3 study cohorts
| Fold Rise | Cohort 1 (4-week Boost Vaccination) | Cohort 2 (8-week Boost Vaccination) | Cohort 3 (12-week Boost Vaccination) |
|---|---|---|---|
| 28-Days post First Dose: GMFR (geometric mean fold rise) | 1.8 (1.2 to 2.7) | 2.5 (1.2 to 5.4) | 2.6 (1.3 to 5.1) |
| 28-Days post Second Dose: GMFR (geometric mean fold rise) | 2.5 (1.5 to 4.1) | 2.4 (1.3 to 4.3) | 3.1 (1.8 to 5.1) |
Comparison of frequency, duration, and severity of solicited symptom events in participants
| events | Cohort 1 (4-week Boost Vaccination) | Cohort 2 (8-week Boost Vaccination) | Cohort 3 (12-week Boost Vaccination) |
|---|---|---|---|
| Fever: Total | 0 | 0 | 0 |
| Fever: Mild | 0 | 0 | 0 |
| Fever: Moderate | 0 | 0 | 0 |
| Headache: Total | 5 | 1 | 5 |
| Headache: Mild | 4 | 1 | 3 |
| Headache: Moderate | 1 | 0 | 2 |
| Myalgia: Total | 2 | 1 | 2 |
| Myalgia: Mild | 2 | 0 | 2 |
| Myalgi: Moderate | 0 | 1 | 0 |
| Abdominal Pain: Total | 2 | 2 | 3 |
| Abdominal Pain: Mild | 2 | 1 | 2 |
| Abdominal Pain: Moderate | 0 | 1 | 1 |
| Anorexia: Total | 1 | 0 | 0 |
| Anorexia: Mild | 1 | 0 | 0 |
| Anorexia: Moderate | 0 | 0 | 0 |
| Nausea: Total | 1 | 0 | 2 |
| Nausea: Mild | 1 | 0 | 2 |
| Nausea: Moderate | 0 | 0 | 0 |
| Vomiting: Total | 1 | 0 | 2 |
| Vomiting: Mild | 1 | 0 | 2 |
| Vomiting: Moderate | 0 | 0 | 0 |
| Diarrhea: Total | 3 | 2 | 4 |
| Diarrhea: Mild | 2 | 1 | 3 |
| Diarrhea: Moderate | 1 | 1 | 1 |
| Malaise/Fatigue: Total | 3 | 1 | 3 |
| Malaise/Fatigue: Mild | 2 | 1 | 2 |
| Malaise/Fatigue: Moderate | 1 | 0 | 1 |
Comparison of the frequency, duration, and severity of unsolicited AEs and serious AEs (SAEs) including AEs of Special Interest (AESIs) and new onsets of chronic illness (NOCIs) in participants
| events | Cohort 1 (4-week Boost Vaccination) | Cohort 2 (8-week Boost Vaccination) | Cohort 3 (12-week Boost Vaccination) |
|---|---|---|---|
| Syncope (Mild) | 1 | 0 | 1 |
| Toothache (Mild) | 0 | 0 | 1 |
| COVID-19 Pneumonia (Severe) | 0 | 1 | 0 |
Frequency, duration, and severity of all SAEs, AESIs and NOCIs through 6 months after last vaccination.
Results for this outcome have not been posted.
Comparison of VPI specific immunoglobin A (IgA) ASC levels by Mesoscale Discovery (MSD) assay between the 3 study cohorts
| Fold rise | Cohort 1 (4-week Boost Vaccination) | Cohort 2 (8-week Boost Vaccination) | Cohort 3 (12-week Boost Vaccination) |
|---|---|---|---|
| 28-Days post the First Dose: GMFR (geometric mean fold rise) | 4.6 (1.6 to 13.6) | 8.9 (3.9 to 20.5) | 11.3 (3.4 to 37.0) |
| 28-Days post the Second Dose: GMFR (geometric mean fold rise) | 3.3 (1.3 to 8.5) | 5.4 (2.5 to 11.7) | 8.9 (2.9 to 26.8) |
Collected over 6 months following boost dose. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 (4-week Boost Vaccination) | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| Cohort 2 (8-week Boost Vaccination) | 0/10 (0%) | 1/10 (10%) | 3/10 (30%) |
| Cohort 3 (12-week Boost Vaccination) | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| Event | Cohort 1 (4-week Boost Vaccination) | Cohort 2 (8-week Boost Vaccination) | Cohort 3 (12-week Boost Vaccination) |
|---|---|---|---|
| COVID-19 PneumoniaInfections and infestations | 0/10 | 1/10 | 0/10 |
| HospitalizationInvestigations | 0/10 | 1/10 | 0/10 |
| Event | Cohort 1 (4-week Boost Vaccination) | Cohort 2 (8-week Boost Vaccination) | Cohort 3 (12-week Boost Vaccination) |
|---|---|---|---|
| HeadacheNervous system disorders | 5/10 | 1/10 | 5/10 |
| DiarrheaGastrointestinal disorders | 3/10 | 2/10 | 4/10 |
| Abdominal PainGastrointestinal disorders | 2/10 | 2/10 | 3/10 |
| FatigueGeneral disorders | 3/10 | 1/10 | 3/10 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/10 | 1/10 | 2/10 |
| NauseaGastrointestinal disorders | 1/10 | 0/10 | 2/10 |
| VomitingGastrointestinal disorders | 1/10 | 0/10 | 2/10 |
| AnorexiaMetabolism and nutrition disorders | 1/10 | 0/10 | 0/10 |
| ToothacheGastrointestinal disorders | 0/10 | 0/10 | 1/10 |
| SyncopeNervous system disorders | 1/10 | 0/10 | 1/10 |
| Age, Categorical(Participants) | Cohort 1 (4-week Boost Vaccination) | Cohort 2 (8-week Boost Vaccination) | Cohort 3 (12-week Boost Vaccination) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 10 | 10 | 30 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Cohort 1 (4-week Boost Vaccination) | Cohort 2 (8-week Boost Vaccination) | Cohort 3 (12-week Boost Vaccination) | Total |
|---|---|---|---|---|
| Mean | 43.2 ± 7.42 | 35.4 ± 9.97 | 34.9 ± 10.09 | 37.8 ± 9.72 |
| Sex: Female, Male(Participants) | Cohort 1 (4-week Boost Vaccination) | Cohort 2 (8-week Boost Vaccination) | Cohort 3 (12-week Boost Vaccination) | Total |
|---|---|---|---|---|
| Female | 4 | 7 | 4 | 15 |
| Male | 6 | 3 | 6 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 (4-week Boost Vaccination) | Cohort 2 (8-week Boost Vaccination) | Cohort 3 (12-week Boost Vaccination) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 3 | 9 |
| Not Hispanic or Latino | 7 | 7 | 7 | 21 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 (4-week Boost Vaccination) | Cohort 2 (8-week Boost Vaccination) | Cohort 3 (12-week Boost Vaccination) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 5 | 3 | 3 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 0 | 4 |
| White | 3 | 5 | 7 | 15 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cohort 1 (4-week Boost Vaccination) | Cohort 2 (8-week Boost Vaccination) | Cohort 3 (12-week Boost Vaccination) | Total |
|---|---|---|---|---|
| United States | 10 | 10 | 10 | 30 |
| Height(centimeter) | Cohort 1 (4-week Boost Vaccination) | Cohort 2 (8-week Boost Vaccination) | Cohort 3 (12-week Boost Vaccination) | Total |
|---|---|---|---|---|
| Mean | 163.23 ± 7.236 | 175.63 ± 7.850 | 166.22 ± 10.734 | 168.36 ± 10.001 |
| Weight(kilogram) | Cohort 1 (4-week Boost Vaccination) | Cohort 2 (8-week Boost Vaccination) | Cohort 3 (12-week Boost Vaccination) | Total |
|---|---|---|---|---|
| Mean | 75.22 ± 9.359 | 86.99 ± 20.457 | 75.54 ± 13.360 | 79.25 ± 15.603 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in Oct 2021, 6 months.
Results were first posted in May 2024, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VXA-G1.1-NN